Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06339008 · ClinicalTrials.gov registry record · Phase 3
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
A Phase 3 study of Perennial Allergic Rhinitis (PAR), sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT06339008 is a Phase 3 study of Perennial Allergic Rhinitis (PAR) that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 450 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06339008, a Phase 3 study of Perennial Allergic Rhinitis (PAR), is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3650150
- DRUG Standard therapy for INCS
Study Locations (20)
California
- Allergy and Asthma Specialists Medical Group - Huntington Beach
- 310 Clinical Research - Inglewood
- Allergy & Asthma Associates of Southern California dba. Southern California Research - Laguna Niguel
- Allergy and Asthma - San Diego
New Jersey
- Circuit Clinical/Hudson-Essex Allergy - Belleville
- Circuit Clinical/Mercer Allergy and Pulmonary Associates - Hamilton
- Dr. Patrick Perin - Teaneck
Florida
- Allergy and Asthma Diagnostic Center - Tallahassee
- University of South Florida - Tampa
Illinois
- Northwestern University - Chicago
- Asthma Allergy Center of Chicago - River Forest
Missouri
- University of Missouri Hospital - Columbia
- Allergy and Asthma Consultants - St Louis
Colorado
- Asthma and Allergy Associates, PC - Colorado Springs
Kentucky
- Bluegrass Allergy Research - Lexington
Michigan
- Respiratory Medicine Research Institute of Michigan, PLC - Ypsilanti
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-04-26 |
| Est. Completion | 2028-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06339008
The ClinicalTrials.gov registry entry for NCT06339008 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Perennial Allergic Rhinitis (PAR) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06339008 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New Jersey, Florida.
Frequently Asked Questions
What is clinical trial NCT06339008 about?
NCT06339008 is a clinical study titled "A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)". The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.
What is the current status of trial NCT06339008?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2024-04-26. Estimated completion is 2028-10.
What conditions does trial NCT06339008 study?
This clinical trial studies the following conditions: Perennial Allergic Rhinitis (PAR).
What interventions are being tested in trial NCT06339008?
The interventions under investigation include: Placebo (DRUG), LY3650150 (DRUG), Standard therapy for INCS (DRUG).
Who is sponsoring clinical trial NCT06339008?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06339008 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.